ReviewTherapeutic advances in chronic disease2016
Ustekinumab in Crohn's disease: evidence to date and place in therapy.
Review in Therapeutic advances in chronic disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease.Frontiers in immunology · 2024Article
- Modern drug discovery for inflammatory bowel disease: The role of computational methods.World journal of gastroenterology · 2023Review
- Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn's disease.Frontiers in medicine · 2023Article
- Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.Therapeutic advances in gastroenterology · 2023Article
- Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn's Disease.International medical case reports journal · 2022Article
- Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.Journal of clinical medicine · 2021Article
- Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease.Journal of clinical medicine · 2021Review
- Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report.BMC gastroenterology · 2020Article
- Article
- A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease.Crohn's & colitis 360 · 2020Article
- The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- Diagnosis and management of inflammatory bowel disease in children.BMJ (Clinical research ed.) · 2017Review
- Insights on the use of biosimilars in the treatment of inflammatory bowel disease.World journal of gastroenterology · 2017Review
- Update on the Use of Biologic Therapy in Ulcerative Colitis.Current treatment options in gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is an inflammatory bowel disease (IBD) with uncertain etiology. Biologic agents have revolutionized the treatment of CD but nonresponders remain a challenge. Ustekinumab is an interleukin 12/23p40 inhibitor that was recently found effective in treating CD. We reviewed the current literature regarding the efficacy of ustekinumab in treating CD and concluded that ustekinumab is a novel, promising and relatively safe agent for the treatment of moderate to severe CD. Additional data from randomized controlled studies and real-life cohorts are pending.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.